Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|C220||PRMT5 Inhibitor 16||C220 is a small molecule inhibitor that selectively targets PRMT5, which may lead to decreased cell proliferation and reduced secretion of cytokines (PMID: 32669286).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|JAK2 V617F||hematologic cancer||predicted - sensitive||C220||Preclinical - Cell culture||Actionable||In a preclinical study, C220 treatment inhibited proliferation of transformed cells expressing JAK2 V617F in culture (PMID: 32669286).||32669286|
|JAK2 V617F||polycythemia vera||predicted - sensitive||C220||Preclinical||Actionable||In a preclinical study, C220 treatment in a transgenic mouse model of polycythemia vera expressing JAK2 V617F resulted in decreased white blood cell counts, reduced spleen size with decreased extramedullary hematopoeisis, and decreased myeloproliferation, and altered the proportion of erythroid progenitors and erythroblasts (PMID: 32669286).||32669286|
|JAK2 V617F||myeloproliferative neoplasm||predicted - sensitive||C220||Preclinical - Cell line xenograft||Actionable||In a preclinical study, C220 treatment inhibited cell proliferation of myeloproliferative neoplasm cell lines, including a Jakafi (ruxolitinib)-persistent cell line, expressing JAK2 V617F in culture, and inhibited tumor growth, with a 71% tumor reduction, in a cell line xenograft model (PMID: 32669286).||32669286|
|JAK2 V617F||myelofibrosis||predicted - sensitive||C220||Preclinical - Patient cell culture||Actionable||In a preclinical study, patient-derived primary myelofibrosis cells harboring JAK2 V617F and positive for CD34 were sensitive to C220 treatment in culture (PMID: 32669286).||32669286|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status||Covered Countries||Other Countries|